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This clinical study describes the intralesional application of the plasmid DNA encoding
two therapeutic species-specific growth factors: vascular endothelial growth factor
(VEGF164) and fibroblast growth factor 2 (FGF2) in seven horses to restore naturally
occurring injuries of the superficial digital flexor tendon (SDFT) (tendinitis) and in three
horses with suspensory ligament branch desmitis. Following application all horses were
able to commence a more rapid exercise program in comparison to standardized
exercise programs. Clinical observation and ultrasonic imaging was used to evaluate
the regeneration rate of the tendon and ligament injury recovery and to confirm the
safety of this gene therapy in horses, throughout a 12 month period. Follow-up data
of the horses revealed a positive outcome including significant ultrasonographic and
clinical improvements in 8 out of 10 horses with SDFT and suspensory ligament branch
lesions, with return to their pre-injury level of performance by 2–6 months after the
completion of treatment. The ninth horse initially presenting with severe suspensory
ligament branch desmopathy, showed no significant ultrasonographic improvements
in the first 2 months after treatment, however, it improved clinically and became less
lame. The final horse, presenting with severe tendinitis of the SDFT returned to their
pre-injury level of performance, but experienced re-injury 6 months after treatment. This
data is highly promising, however, further research in experimental models, with the
histopathological, immunohistochemical and gene expression evaluation of the equine
tendon/ligament after gene therapy application is required in order to fully understand
the mechanisms of action. This treatment and the significant clinical impacts observed
represents an important advancement in the field of medicine.
Keywords: gene therapy, horse, tendon injuries, superficial digital flexor tendon, suspensory ligament, vascular
endothelial growth factor 164, fibroblast growth factor
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INTRODUCTION
The most common causes of orthopedic disorders in horses
are tendon and ligament injuries and are regarded as a career-
limiting disease. It has been estimated that on United Kingdom
racecourses for example 46% of all injuries that occur are tendon
or ligament injuries (Pinchbeck et al., 2004). Injuries of the SDFT
and the SLB are of utmost clinical importance in the horse of all
cases observed in equine practice (Kovac et al., 2002).
The healing response following equine tendon/ligament (T/L)
injuries is predicable. The response has traditionally been divided
into three overlapping stages classified as – inflammation,
proliferation/repair and remodeling. The acute inflammatory
phase (lasting <10 days) includes phagocytosis of damaged
tendon tissue and demarcation of injured tendon tissue. Between
2 and 4 days after injury the proliferative or reparative phase
begins, and can last for approximately 45 days. The main
problem observed is that at in early stages of tendon healing,
increased amounts of collagen type III are observed in the matrix
which is synthesized by tenocytes (Juneja et al., 2013). Type III
collagen is composed of smaller sized fibers in comparison to
type III and has a decreased capacity for elasticity and strength
(Sodersten et al., 2013). The collagen fibrils at approximately
45 days after injury are organized into tendon bundles during
the remodeling phase, which in itself is often divided into
consolidation and maturation phases. During the remodeling
phase tenocytes and collagen fibers become aligned in the
direction of stress. A decrease in collagen type III is observed
with a concomitant increase in type I, and decreases are also
observed in cellularity and glycosaminoglycan contents (Sharma
and Maffulli, 2006).
Because of the high incidence of equine T/L injuries, high
re-injury rate and prolonged recovery period, usually lasting
several months and extending up to 15 months in severe injuries,
these disorders pose a real problem. Over the years a number
of advances in physiotherapy, medical, regenerative and surgical
interventions have been developed and applied, however, these
strategies are often not sufficient in restoring the functional,
structural and biochemical properties of repaired equine T/L to
those observed in native tissue. In many cases the repaired tendon
tissue remains biochemically and ultrastructurally abnormal
even after 12 months and does not completely regain the
biomechanical properties it had prior to injury (Yang et al.,
2013). When using medicinal therapy to treat equine tendon
injuries the disease relapses in more than 43% of cases upon
intensive physical exercise (Dyson, 2004). Despite the promise
Abbreviations: AAEP, American Association of Equine Practitioners; CDU, color
Doppler ultrasonography; CSA, cross-sectional area; EMA, European Medicines
Agency; FDA, food and drug administration; FGF2, fibroblast growth factor 2; LF,
left forelimb; LH, left hindlimb; MIZ, maximal injury zone; MIZ-CSA, maximal
injury zone cross-sectional area; MIZ-ES, maximal injury zone lesion echogenicity
score; MIZ-FAS, maximum injury zone fiber alignment score; MIZ-lesion %,
maximal injury zone lesion percentage; RF, right forelimb; RH, right hindlimb;
SDFT, superficial digital flexor tendons; SLB, suspensory ligament branches; T/L,
tendons/ligaments; T-CSA, total tendon cross-sectional area; T-CSA-L %, total
percentage of the cross-sectional lesion area; T-ES, total echogenicity score of the
lesion; T-FAS, total fiber alignment score; VEGF164, vascular endothelial growth
factor.
of regenerative medicine methods, such as the use of autologous
bone marrow and adipose tissue derived mesenchymal stem cells,
as well as platelet rich plasma (Godwin et al., 2012; Middleton
et al., 2012; Uysal et al., 2012; Kovac et al., 2016; Witte et al.,
2016) which continued to grow since their inception over 10 years
ago, translation of experimental models research into clinical
therapies by severe equine T/L damage has been frustratingly
slow.
The equine tendon is a relatively poorly vascularized
tissue. During tendon injury, which is characterized by focal
hypocellularity, collagen fibril degeneration, ischemia and
fibroblast anoxia, the vascular system is required in order to allow
cell infiltration which in turn provides the necessary reparative
factors for tissue healing (Docheva et al., 2015). Tenocytes and
their extracellular matrix in the form of subunits called fascicles,
are surrounded by small amounts of loose connective tissue
termed the endotenon. The endotenon carries blood vessels,
which do not penetrate the fascicular substance under normal
circumstances (Fenwick et al., 2002). The process of angiogenesis
is controlled by a variety of mitogenic, chemotactic, or inhibitory
peptides and lipid factors (Snedeker and Foolen, 2017). One of
the aims of our study was to correct this fundamental problem
in horses by stimulating neovascularization/angiogenesis, thus
providing the necessary reparative factors during the early tendon
healing period. To this end a gene therapy approach using
VEGF164 and FGF2 was utilized.
It has been suggested that the ‘use of recombinant proteins and
gene therapy are the most advanced and promising approaches
in the treatment of musculoskeletal disorders in human
medicine’ (Martinek et al., 2005). Angiogenesis is indispensable
for regeneration tissue therefore targeted manipulation of
this network may offer unique opportunities for regenerative
veterinary medicine. We used plasmid DNA containing FGF2
and VEGF164 as they are known to promote soft tissue
regeneration. FGF plays minor roles in stages inflammation and
remodeling but major roles in stage proliferation/repair and
induces VEGF expression – a pivotal factor in the regulation of
normal vasculogenesis and angiogenesis (Seghezzi et al., 1998).
Several studies have also shown that VEGF can increase the
efficiency of skeletal muscle repair by increasing angiogenesis
and, at the same time, reducing the accumulation of fibrosis (Best
et al., 2013). The plasmid construct pBUDK-ecVEGF164-ecFGF2
was generated as previously described on a pBudCE4.1 vector
(Litvin et al., 2016).
The gene therapy approach we recently used in two horses that
had gone lame due to injury of the suspensory ligament branch
and SDFT resulted in rapid recovery within 2 to 3 weeks (Kovac
et al., 2017). Within just 3 months they were back to full health,
galloping and competing. The aim of the present study was to
provide further clinical proof that a single intralesional injection
of plasmid DNA containing species-specific VEGF164 and FGF2
cDNAs has long term clinical and ultrasonographic detectable
effect in the treatment of acute and subacute injury of the SLB and
SDFT. Clinical assessment and ultrasonic imaging at 12-month
follow-up was used in a greater number of horses (10 in total) to
evaluate the regeneration rate of the tendon and ligament, and
to confirm the safety of this gene therapy. In addition CDU was
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utilized in order to understand the vasculature of the affected
regions in order to further understand the mechanism of action
of the gene therapy.
MATERIALS AND METHODS
Study Design
Ten horses with naturally occurring SDFTs and SLB lesions
were enrolled onto the study from 2015 to 2017 and treated
at the Equine Clinic – New Century of the Moscow State
Academy of Veterinary Medicine and Biotechnology, Moscow.
The study included seven horses with middle and severe SDFT
tendinitis and three horses with desmitis of the SLBs. The horses
enrolled on this study were required to meet the following
criteria prior to enrollment: acute and subacute tendinitis of
SDFT or SLB desmitis, which showed ultrasonographically
recognizable hypoechoic lesion occupying >12% of the CSA at
the maximum injury zone within an intact paratenon, and a
severity of abnormal echogenicity and fiber alignment in which
both grades were 3 or higher on a scale from 0 to 4. In addition
horses were only included if the clients provided informed
consent and if horses had not receive previous intra-tendinous
injections.
The owner reported duration from horse injury until
initial examination and treatment within the equine clinic was
16.05 days (±14.23), and ranged from 3 to 45 days (Table 1).
All horses were adults from the following breeds: 3 Hanoverian,
2 Trakehner, 1 Dutch Warmblood, 1 Andalusian, 1 Russian
Saddle Horse, 1 Orlov Trotter and 1 Budyonny Horse. The study
included 6 gelder, 2 mares and 2 stallions. The average age of the
horses was 9.8 years (±2.78), and ranged from 6 to 15 years. The
horses involved were mainly used for dressage (8 cases) but one
was used for jumping and the other was a pleasure/riding horse
(Table 1).
Prior to treatment, all horses underwent clinical examinations
(lameness grade), including perineural or intra-articular to
precisely localize the lesion. Lameness was evaluated with
horses walking and trotting in hand in a straight line, and
by lunging on hard and soft surfaces. All the observations
and determinations were made by the same veterinarian (M.
K.), and were always made on the same ground surface.
Lameness diagnosis was performed and scored from 0 to
5 only using the AAEP scale, on which grade 0 represents
sound ability and grade 5 indicates non-weight bearing capacity.
The signs of inflammation in the palmar metacarpal/plantar
metatarsal region (skin surface temperature, swelling, and
painful sensitivity to palpation) were also monitored. In these
horses with SDFT tendinitis and SLB desmitis, there were
no findings of clinical relevance in radiographic examinations
in proximal sesamoid bones or any other joints of the lame
limb.
Ultrasonographic Examination
Ultrasonographic examination of the equine T/L was performed
using a 7.5-MHz linear-array transducer (Logiq 5, GE Healthcare,
WI, United States), after routine clipping. The type of T/L
lesion was determined on transverse images in the MIZ
(core lesion = centrally located, focal hypo-/anechoic region;
marginal lesion = peripherally located, focal hypo-/anechoic
region; diffuse lesion = homogenous or heterogenous changes
in echogenicity of the whole/most parts of the cross sectional
area). A modified ultrasound classification for SDFT was
TABLE 1 | Description, clinical history and diagnostic data of 10 horses before treatment with plasmid DNA encoding VEGF164 and FGF2 genes.
Horse
no.
Gender Breed Age
(years)
Discipline Reported duration
injury until initial
examination (days)
Veterinary
diagnosis
Injury zone of
affected limb and
lesion type
Lameness
grade before
treatment
1 Gelding Hanoverian 13 Dressage 7 days Suspensory
ligament branch
desmopathy
RF 3b lat, Marginal 3
2 Gelding Andalusian 11 Dressage 14 days Suspensory
ligament branch
desmopathy
LF 3b med, Marginal 2
3 Gelding Hanoverian 9 Dressage 25 days Suspensory
ligament branch
and body
desmopathy
LH 3a-4b med, Diffuse 3
4 Mare Dutch Warmblood 7 Dressage 32 days SDFT tendinitis LF 2b, Marginal 1
5 Gelding Trakehner 11 Jumper 3 days SDFT tendinitis RF 1b, Marginal 2
6 Gelding Orlov Trotter 8 Pleasure 12 days SDFT tendinitis LF 1b, Diffuse 3
7 Stallion Trakehner 6 Dressage 45 days SDFT tendinitis LF 1a-2a, Core 2
8 Gelding Russian Saddle
Horse
10 Dressage 10 days SDFT tendinitis and
annular ligament
desmopathy
RF 3c, Marginal 2
9 Mare Budyonny Horse 8 Dressage 4 days SDFT tendinitis RF 1b, Marginal 2
10 Stallion Hanoverian 15 Dressage 6 days SDFT tendinitis RF 2b, Core 1
RF, right forelimb; LF, left forelimb; RH, right hindlimb; LH, left hindlimb; SDFT, superficial digital flexor tendon.
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used (Rantanen et al., 2003), with evaluation of the following
parameters: total cross-sectional area (T-CSA in mm2), total
percentage of the cross-sectional lesion area (T-CSA-L %; lesion
area/tendon area × 100), T-ES, and the T-FAS. The T-CSA was
calculated by summing the CSA of the SDFT in 6 different zones
(1A to 3B). The total lesion percentage was calculated as follows:
(T-CSA-L/T-CSA)× 100. The severity of the tendon or ligaments
lesion was assessed ultrasonographically using the criteria: mild
0–15 of CSA-L %, middle 16–25 of CSA-L % and severe >25 of
CSA-L %. Echogenicity was assigned a score of 0 (normoechoic),
1 (hypoechoic), 2 (mixed echogenicity), or 3 (anechoic) and fiber
alignment was graded according to the estimated percentage of
parallel fiber bundles in the lesion: 0 (>75%), 1 (50–74%), 2 (25–
49%), and 3 (<25%). Scores for all levels were summarized to
calculate the total echo score and the T-FAS, respectively.
Ultrasound evaluation of the SLB was performed from the
palmaromedial and palmarolateral aspects of both limbs. Three
equidistant transverse and longitudinal images were obtained
for SL branches, and at the level of the sesamoidean insertion.
A modified ultrasound evaluation for SLB lesions was used: MIZ-
CSA, percentage lesion at the maximum injury zone MIZ, the
echogenicity score of the lesion at the MIZ and the percentage
disruption of the longitudinal fibers at the MIZ, and also
ultrasound evidence of sesamoid bone margin irregularity or
disruption at the level of ligament insertion.
The lesion regions of the SDFT and SLB were also evaluated
using CDU. Before performing the CDU, the MIZ of the lesion
was located with B-mode ultrasonography while the limb was
weight-bearing. In order to carry out the CDU, the hoof was
placed in a Hickman (Oxspring) block with the digit in slight
extension and the carpus flexed at an angle of 80–90◦, in order
to avoid the possible occlusion of small blood vessels due to
mechanical forces. For CDU the settings were established at
10 MHz Doppler frequency, and a pulse repetition frequency
of 1.5 kHz. To avoid artifacts, settings were optimized for
low flow, and Doppler gain was set just below random noise
(VEL/6.2 MHz; 0 Db). Care was taken to minimize pressure
exerted by the transducer. The tendons were examined in the
longitudinal plane in close proximity to the abnormal areas with
a transducer without standoff. The transducer was kept at each
site for at least 30 s in lateral, middle, and medial positions,
on the tendon to evidence the greatest possible blood flow.
The recordings of each CDU session were digitally stored as a
videoclip for subsequent DICOM assessment of the vascularity at
the end of the study by means of scoring on a semi-quantitative
grading scale. On this scale, grade 0 indicated no detectable blood
vessels, grade 1 one to two small vessels, grade 2 several small
or one to two larger vessels, grade 3 several larger vessels and
grade 4 diffuse vascularization, as previously described (Bosch
et al., 2011). A clinician blinded to treatment performed the data
acquisition, measurements were analyzed and retrospectively for
each animal a mean scoring of the lame and also contralateral
limb at various time points was produced (R.A).
Plasmid DNA Drug
Plasmid DNA pBUDK-ecVEGF164-ecFGF2 design was as
described previously (Litvin et al., 2016). The plasmid DNA
(pDNA) contained coding sequences of Equus caballus protein
growth factors Vascular endothelial growth factor A 164
(VEGFA164) and fibroblast growth factor 2 (FGF2/bFGF).
Plasmid DNA preparation was conducted by GenScript as
part of an SC Grade service which guarantees final product
purity ≥95% in a supercoiled form with an endotoxin
level of ≤0.03 EU/mg pDNA. No additional tests were
conducted to verify product purity or percentage present
in supercoiled form. VEGF164 and FGF2 were cloned into
different expression cassettes under the control of different
strong constitutive promoters (Litvin et al., 2016). Our
previous work demonstrated high levels of recombinant
protein production as shown by immunofluorescence and
western blot analysis (Litvin et al., 2016). Descriptions of
VEGFA164 and FGF2, alongside the efficiencies of these
gene combinations have been shown in our previous work
(Plotnikov et al., 2012; Litvin et al., 2016; Kovac et al.,
2017).
Preparation and Administration of the
Plasmid DNA
Plasmid DNA preparation, storage and administration was as
described previously (Kovac et al., 2017). In short, plasmid DNA
was dissolved in 5 ml of a sterile 0.9% NaCl solution to a final
concentration of 1 mg/ml. This solution was stored in a fridge at
+4◦C˜ overnight, with occasional gentle stirring and rotation. The
pDNA solution was warmed to +37◦C˜ prior to administration
into damaged tissue. Before treatment, horses were sedated with
detomidine (0.01–0.03 mg/kg intravenously). 3.5 ml total volume
of the pDNA solution was drawn into a syringe and under
aseptic conditions and sonographic guidance the solution was
slowly injected using a 22-gauge needle into sites of injury,
whilst the limb was weight-bearing. The filled volume was multi-
injected into the most hypoechoic areas of tissue damage and
adjacent normal tissues. pDNA was administered on only one
occasion per animal in order to treat the tendon and ligament
injury.
Horse Rehabilitation and Evaluation
Following Plasmid DNA Gene Therapy
Following injection of the plasmid DNA, a bandage was applied
to the limb. Horses were hospitalized for 10 days after procedure
for observation and then discharged. Special attention was given
to detecting any possible clinical signs of local immunological
reactions, including increases in temperature, tissue swelling
and lameness. The rehabilitation plan was individually tailored
according to the severity of the injury and in relation to
results from the clinical and ultrasonographic evaluations
throughout the healing process. A controlled exercise program
was initiated. We monitored the progress of tendon healing
with a modification equine tendon healing criteria according to
an already established method (Gillis, 1997), using measurable
ultrasound criteria such as the percentage of the cross-sectional
lesion, total echo-score and T-FAS. The progress of the SLB
healing were also monitored using measurable ultrasound
criteria such as the cross sectional area, the percentage lesion
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at the maximum injury zone, the echogenicity score of the
lesion and the fiber alignment score at the maximum injury
zone.
The management and rehabilitation program were carefully
matched to the progress of healing. As was often noticed in our
treated horses, significant clinical and ultrasound improvements
were observed at relatively early time periods in comparison
to normal tendon healing methods (without gene therapy). In
these cases these horses we able to advance more quickly through
the exercise program in comparison to those usually prescribed
for traditional treatments, this was also in line with previously
established techniques (Bosch et al., 2011; Watts et al., 2011).
After stall rest for the first 2 days after treatment, the
animals were maintained at a low-level of exercise activity
(hand walking) for a 3-week period. Then, when symptom-
free, after a warm-up walk, most of the horses trotted for 1–
3 min on firm flat ground mainly in straight lines, increasing
intensity and time duration every week until entering a complete
training protocol including walking, trotting and galloping.
Each component of the exercise program was shortened or
lengthened on the basis of ultrasonography evidence of healing
progression (i.e., healing of the defected tissue) and severity
of lameness. The specific exercise program 20 weeks after the
administration plasmid DNA was usually mostly determined
by the owner/trainer to reflect the normal workload of the
horse.
Serial clinic and ultrasound examinations to evaluate the
regeneration rate of the T/L injury recovery and to confirm the
safety of this gene therapy in horses, were performed for all
treated horses: before treatment (day 0), every 20 days in the
first 2 months after treatment, then every 30 days in months
3–4 and then every 60 days until the end of the study. At
the 12-month follow-up, lameness grade, the time required to
return to pre-injury activity level and ultrasonography were
also re-evaluated. The treatment was considered to have been
successful when the horse returned to its pre-injury training or
competition level, without a relapse of the injury during the
follow-up time.
Statistical Analysis
Analysis of data was performed using SPSS 15.0. Quantitative
data were evaluated by paired T-test. The level of significance was
considered as p < 0.05. All values in the graphs are expressed as
arithmetic mean values with standard deviations.
Ethics
Plasmid vectors were created in accordance with the human
standards set by the United States Food and Drug Administration
(FDA, 2007, 2008), and the Committee for the Medicinal
Products for Human Use in the European Medicines Agency
(EMA, 2001, 2006, 2007). The Institutional Review Board of the
Kazan Federal University approved this study (protocol No. 3;
date 05.05.2015) in addition to the institutional committees of
Moscow State Academy and the University of Nottingham, all
national guidelines were adhered to. The horses presented at the
clinic with naturally occurring injuries and informed consent was
given by owners. This technique has been previously successfully
used in dogs (Zakirova et al., 2014) and humans (Plotnikov
et al., 2012). Injections and care were given in accordance with
standard veterinary practice recommendations and undertaken
by qualified clinicians with additional health and welfare
checks and clinical observations. Anatomical nomenclature
followed the Nomina Anatomica Veterinaria 2017 (ICVGAN,
2017).
RESULTS
Evaluation of Horses With
SLB-Desmopathy
In horses with SLB, desmitis presented with marginal lesions (two
limbs) and diffuse lesion (one limbs). Prior to treatment horse #3
had a diffuse lesion not only branch and also moderate damage
of the body suspensory ligament of the same leg. In all cases
the contralateral limb had either no significant abnormalities on
ultrasound. Only horse #1 had ultrasonographic signs of scarring
of the SDFT in the contralateral non-lame limb on day 0. Prior
to treatment, pain of the ligament by digital pression was noted
in all three horses, horses were checked from day 0 until the
end of the study. Twenty days after treatment no pain was
noted by digital pression at the injury level in horse #1, by day
40 after treatment none of the recorded animals had signs of
inflammation in the palmar metacarpal/plantar metatarsal at the
lesion region, there were no skin surface temperature changes,
swelling, or painful sensitivity to palpation. One horse (#1)
returned to pre-injury, sport activity level within 2–6 months of
treatment and rehabilitation and s no lameness and participated
in competitive dressage tournaments from after the rehabilitation
time up to the present day (at the time of manuscript submission).
Horse #2 was considered sound following rehabilitation and
returned to sporting activity but at a lower level. Horse #3
(SLB) remained lame during the first 3 months of treatment,
but there was negligible improvement detected in the degree of
lameness and response to the flexion test and after 90 days the
lameness was not evident, but this horse not return to sporting
activity.
Horses were observed for adverse reactions from day 0 until
the end of the 12 month study. In 2 of the 3 enrolled horses no
adverse reactions were observed as a result of the application
of the pDNA. Horse #2 showed a minor adverse reaction on
the 5th day following administration of the pDNA. The reaction
presented as a painless edema and thickening of the subcutaneous
tissue in the tissue surrounding the injection point, the edema
and swelling gradually disappeared within 10 days. Prior to
treatment, on day 0, the mean degree of lameness was 2.67± 0.58
in the study horses (Figure 1A). In particular horses #1 and #3
showed high degrees of lameness before treatment (Table 2).
Compared to day 0, lameness significantly decreased by day
20 after treatment to 1.33 ± 0.58 (p < 0.05; Figure 1). At
12 weeks and persistently in later follow-up examinations, no
lameness was evident by clinical examination in any of the three
treated horses. The owners were asked to score their horses
performance 12 months after gene therapy. Athletic success was
reported as good to excellent by 2 out of 3 owners. The owners
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FIGURE 1 | Degree of the lameness in horses with SLB lesions (A) and SDFT (B) after treatment with plasmid DNA encoding VEGF164 and FGF2 genes. ∗ Indicates
point at which p < 0.05 was reached in comparison to day 0.
TABLE 2 | Degree of the lameness after treatment of SLB and SDFT over time.
Horse number/days after
treatment
SLB SDFT
1 2 3 Mean ± SD 4 5 6 7 8 9 10 Mean ± SD
Day 0 3 2 3 2.67 ± 0.58 1 2 3 2 2 2 1 1.86 ± 0.69
Day 20 1 1 2 1.33 ± 0.58 0 1 1 0 0 1 0 0.43 ± 0.53
Day 40 1 0 2 1.00 ± 1 0 1 1 0 0 1 0 0.43 ± 0.53
Day 60 0 0 2 0.67 ± 1.15 0 1 1 0 0 0 0 0.29 ± 0.49
Day 90 0 0 2 0.67 ± 1.15 0 0 0 0 0 0 0 0 ± 0
Day 120 0 0 0 0 ± 0 0 0 0 0 0 0 0 0 ± 0
Day 180 0 0 0 0 ± 0 0 3 0 0 0 0 0 0.43 ± 1.13
Day 240 0 0 0 0 ± 0 0 1 0 0 0 0 0 0.14 ± 0.38
Day 300 0 0 0 0 ± 0 0 0 0 0 0 0 0 0 ± 0
Day 360 0 0 0 0 ± 0 0 0 0 0 0 0 0 0 ± 0
of horse #3 (the horse that showed lameness within the first
3 months) could not report good-excellent athletic success at that
point. The age of the horses and duration of lameness did not
show any influence on the clinical outcome after gene therapy.
The main differences in the clinical outcomes were observed
in relation to the degree and location of T/L damage before
treatment.
Table 3 shows the ultrasonographic measurements of the
three horses with SLB desmopathy before and after treatment
with plasmid DNA encoding VEGF164 and FGF2 genes. On the
basis of CSA scale of suspensory ligament branch involved in
the injury, horses #1 and #2 before treatment showed moderate
marginal an- and hypoechoic areas lesions and disruption of
fiber pattern, together with enlargement and periligamentar
fibrosis in fore limbs (right for horse #1 and left in horse #2).
Only in horse #3 was the damage present in the left hindlimb
(Table 3). In this horse diffuse altered echogenicity of SLB, poor
differentiation of ligament margins, periligamentous echogenic
material subcutaneously and also middle lesion of suspensory
ligament body were noted. In all three cases with SLB desmitis
the contralateral limb had no significant abnormalities upon
ultrasound before treatment. Supplementary Figure S1 shows
ultrasound images prior to and following treatment. The mean
CSAs of the MIZ for SLB before treatment, was 1.98 cm2, and
the mean of the MIZ-lesions were 30.44% (these ranged from
25.45 to 37.13%; Table 3). The echogenicity scores and the
percentage disruption of the longitudinal fibers of the lesion at
the maximum injury zone before treatment was on average 3
(Table 3).
Ultrasound characteristics of SLB desmopathy in horses
#1 and #2 had started to improve at the checks performed
20 days after treatment, and the healing process was constantly
maintained in latter follow-ups. This was especially noticeable
in the following parameters: MIZ-lesion % (Figure 2A), the
echogenicity (Figure 2B) and the fiber alignment score at the
maximum injury zone (Figure 2C). Mean MIZ-CSA of the
branch of suspensory ligaments did not change significantly
throughout the observation period (Figure 2D). When these
horses started the exercise program, ligament architecture
improved constantly, as demonstrated by their longitudinal
alignment and length (Figure 3). According to our observations,
there was no substantial improvement in the first 90 days after
treatment in all ultrasonographic parameters in horse #3 with SLB
desmitis. On days 20 and 40 this horse showed new hypoechoic
lesions, indicating an unstable healing process. Only on days
120–180 after treatment did this horse present with noticeable
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TABLE 3 | Ultrasonographic results in horses with SLB desmitis before and after treatment with plasmid DNA encoding VEGF164 and FGF2 genes.
Day after treatment US-parameter Horse 1 Horse 2 Horse 3 Mean ± SD
Day 0 MIZ-CSA (cm2) 1.92 1.77 2.25 1.98 ± 0.20
MIZ-lesion % 25.45 28.76 37.13 30.44 ± 4.91
MIZ-ES 3 3 3 3.00 ± 0.00
MIZ-FAS 3 3 3 3.00 ± 0.00
Day 20 MIZ-CSA 1.66 1.72 1.85 1.74 ± 0.08
MIZ-lesion % 18.43 16.67 36.63 23.91 ± 9.02
MIZ-ES 2 2 3 2.33 ± 0.471
MIZ-FAS 2 3 3 2.66 ± 0.47
Day 40 MIZ-CSA 1.65 1.56 1.99 1.73 ± 0.18
MIZ-lesion % 12.36 10.46 26.73 16.51 ± 7.26
MIZ-ES 1 1 2 1.33 ± 0.47
MIZ-FAS 2 2 3 2.33 ± 0.47
Day 60 MIZ-CSA 1.53 1.48 1.78 1.59 ± 0.13
MIZ-lesion % 8.78 10.57 24.33 14.56 ± 6.94
MIZ-ES 1 1 2 1.33 ± 0.47
MIZ-FAS 2 2 3 2.33 ± 0.47
Day 90 MIZ-CSA 1.60 1.47 1.86 1.64 ± 0.16
MIZ-lesion % 3.37 6.68 19.25 9.76 ± 6.84
MIZ-ES 1 1 2 1.33 ± 0.47
MIZ-FAS 1 2 3 2.00 ± 0.81
Day 120 MIZ-CSA 1.47 1.57 1.70 1.58 ± 0.09
MIZ-lesion % 3.57 4.78 15.86 8.07 ± 5.53
MIZ-ES 1 1 2 1.33 ± 0.47
MIZ-FAS 1 1 2 1.33 ± 0.47
Day 180 MIZ-CSA 1.40 1.34 1.72 1.48 ± 0.17
MIZ-lesion % 2.41 3.34 12.89 6.21 ± 4.73
MIZ-ES 0 1 2 1.00 ± 0.81
MIZ-FAS 1 1 2 1.33 ± 0.47
Day 240 MIZ-CSA 1.45 1.54 1.72 1.57 ± 0.11
MIZ-lesion % 3.71 2.08 10.99 5.59 ± 3.87
MIZ-ES 0 0 1 0.33 ± 0.47
MIZ-FAS 1 1 2 1.33 ± 0.47
Day 300 MIZ-CSA 1.47 1.59 1.85 1.63 ± 0.15
MIZ-lesion % 1.67 1.98 8.80 4.15 ± 3.29
MIZ-ES 0 0 1 0.33 ± 0.47
MIZ-FAS 0 0 2 0.66 ± 0.94
Day 360 MIZ-CSA 1.52 1.55 1.79 1.62 ± 0.12
MIZ-lesion % 0.84 1.15 7.96 3.31 ± 3.28
MIZ-ES 0 0 1 0.33 ± 0.47
MIZ-FAS 0 0 2 0.66 ± 0.94
MIZ-CSA, maximal injury zone cross-sectional area; MIZ-lesion %, percentage lesion at the maximum injury zone; MIZ-ES, echogenicity score of the lesion at the maximum
injury zone; MIZ-FAS, the fiber alignment score at the maximum injury zone.
improvement of the MIZ-lesion %, the echogenicity and the fiber
alignment score.
The evaluated T/L lesions using CDU showed that in most
horses with SLB-desmopathy before treatment, only small color
foci that were rhythmically blinking at the lesion area were
present. The average color Doppler scores for vascularization
of maximal inquires zone for SLB before treatment was 1.27
(±0.21), this was slightly elevated in comparison to healthy
contralateral limbs (0.8 ± 0.52). Color Doppler scores for
vascularization of maximal inquires zone for SLB limbs after
treatment with the plasmid DNA encoding VEGF164 and FGF2
genes, revealed a notable increase in scores by just day 20
(2.97 ± 0.93; Table 4 and Figures 4, 5). The increase continued
at day 40 (0.03 ± 0.68), with elevated levels continuing until
day 90. The CDU scores in most animals then gradually
decreased to basal indices (as in healthy limbs) after 180 days
of treatment, indicating blood flow patterns similar to day 0
(Figure 4). No significant correlation was observed between the
severity of T/L lesions prior treatment and CDU scores after
treatment. Horse #2 after 20 days of treatment showed a very
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FIGURE 2 | Effects of plasmid DNA encoding VEGF164 and FGF2 genes in horses with SLB desmopathy. The (A) percentage of total cross sectional lesion area
lesion, (B) echogenicity score of the lesion, (C) fiber alignment score of the lesion, and (D) cross-sectional area of the suspensory ligament branch, at the maximal
injury zone. ∗ indicates point at which p < 0.05 was reached in comparison to day 0.
high CDU score of 4. This horse, as previously mentioned, had
a slight local reaction on days 5–10 at the site of plasmid DNA
injection.
Evaluation of Horses With
SDFT-Tendinitis
The horses included with SDFT tendinitis presented with core
lesions (two limbs), marginal lesions (four limbs) and diffuse
lesions (six limbs) (Table 2). In horse #8 with acute SDFT
lesions in zone 3c, mild damage of the annular ligament and
accumulation of the synovial fluid within of the tendon sheath
were also detected in the same leg. In all cases the contralateral
limb had either no significant abnormalities on ultrasound.
Only horses #5 had ultrasonographic signs of scarring of the
SDFT in the contralateral non-lame limb on day 0. Prior to
treatment, pain of the tendon by digital pression was noted
in six of the seven horses, only horse #7 with core lesion
of SDFT did not show pain before the treatment. Twenty
days after treatment no pain was noted by digital pression
TABLE 4 | Color Doppler scores for vascularization of maximal inquiries zone for SLB and SDFT after treatment with the plasmid DNA encoding VEGF164 and FGF2
genes.
Days after treatment/ SLB SDFT
horse number
1 2 3 Mean ± SD 4 5 6 7 8 9 10 Mean ± SD
Day 0 1.2 1.5 1.1 1.27 ± 0.21 1.1 1.3 0.9 1.0 1.3 1.6 0.7 1.13 ± 0.30
Day 20 2.2 4.0 2.7 2.97 ± 0.93 1.7 2.1 1.8 3.2 2.6 3.1 2.1 2.37 ± 0.60
Day 40 2.5 3.8 2.8 3.03 ± 0.68 2.6 2.7 2.3 2.8 3.1 3.4 2.9 2.83 ± 0.35
Day 60 2.1 2.7 2.4 2.40 ± 0.30 2.8 2.8 1.4 2.1 3.2 2.8 3.2 2.61 ± 0.65
Day 90 2.8 2.4 2.5 2.57 ± 0.21 3.2 3.1 2.8 1.8 2.4 2.5 2.9 2.67 ± 0.48
Day 120 1.2 1.1 1.4 1.23 ± 0.15 1.8 2.1 2.4 1.4 1.1 1.8 1.6 1.74 ± 0.43
Day 180 1.0 1.0 1.1 1.03 ± 0.06 1.2 2.5 1.2 1.2 1.5 0.9 0.8 1.33 ± 0.56
Day 240 0.8 1.1 1.6 1.17 ± 0.40 1.6 1.9 1.7 1.1 0.9 1.0 1.7 1.41 ± 0.40
Day 300 0.9 1.4 0.9 1.07 ± 0.29 0.9 1.0 0.6 0.6 0.8 0.9 0.8 0.80 ± 0.15
Day 360 0.6 0.6 0.9 0.70 ± 0.17 1.0 0.8 0.6 0.8 0.9 0.7 0.6 0.77 ± 0.15
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FIGURE 3 | Ultrasound images prior to plasmid DNA encoding VEGF164 and FGF2 genes on day 0 (A), 20 (B), 40 (C), 90 (D), 180 (E), and 300 (F) after
administration in horse #2 – SLB desmopathy. Arrows indicate lesion.
FIGURE 4 | The mean color Doppler scores for vascularization of maximal inquiries zone for (A) SLB and (B) SDFT after treatment with the plasmid DNA encoding
VEGF164 and FGF2 genes. ∗ indicates p < 0.05 in comparison to day 0.
FIGURE 5 | Transverse and longitudinal color Doppler ultrasonography projections prior to plasmid DNA encoding VEGF164 and FGF2 genes (A) and 20 (B),
40 (C), 90 (D), 180 (E), 360 (F) days after administration in horse #2 – SLB desmopathy.
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at the injury level in six of the seven horses. (horses #4, #5,
#7, #8, #9, and #10). By day 40 after treatment none of the
recorded animals had signs of inflammation in the palmar
metacarpal/plantar metatarsal at the lesion region, there was no
skin surface temperature changes, swelling, or painful sensitivity
to palpation.
Five horses returned to pre-injury, sport activity level within
2–6 months of treatment and rehabilitation and showed no
lameness (horses #4, #5, #7, # 9, and #10). Two of these
horses (#4 and #10), participated in competitive dressage
tournaments from after the rehabilitation time up to the present
day (at the time of manuscript submission). One horse (#8)
was considered sound following rehabilitation and returned
to sporting activity but at a lower level. Horse #5, with
middle acute SDFT tendinopathy, returned to its pre-injury
level of performance, but approximately 6 months after the
treatment, once competitive jumping had resumed, this animal
suffered sudden onset of lameness, which was associated with
TABLE 5 | Ultrasonographic results of the SDFT tendinitis horse before and after treatment with plasmid DNA encoding VEGF164 and FGF2 genes.
Day after treatment US -parameter Horse number Mean ± SD
4 5 6 7 8 9 10
Day 0 T-CSA 935 1272 913 952 867 981 890 972.90 ± 137.30
T-CSA-L % 18.21 23.38 15.62 21.03 14.45 12.03 17.35 17.44 ± 3.88
T-ES 7 9 8 8 7 8 7 7.71 ± 1.29
T-FAS 8 8 7 7 6 7 7 7.14 ± 0.69
Day 20 T-CSA 954 1232 930 958 889 890 845 956.90 ± 127.80
CSA-L % 15.35 20.88 14.27 16.45 11.38 9.04 16.58 14.85 ± 3.83
T-ES 5 5 4 5 4 6 4 4.71 ± 0.75
T-FAS 8 8 6 7 6 6 6 6.71 ± 0.95
Day 40 T-CSA 879 1055 891 939 812 836 809 888.70 ± 86.89
T-CSA-L % 12.56 15.67 11.09 14.43 8.65 9.56 15.94 12.56 ± 2.92
T-ES 4 4 4 3 3 4 5 3.86 ± 0.69
T-FAS 7 7 6 7 6 5 6 6.29 ± 0.75
Day 60 T-CSA 834 1025 865 822 847 988 865 892.30 ± 80.26
T-CSA-L % 10.67 14.04 8.99 11.56 8.01 7.56 14.43 10.75 ± 2.76
T-ES 3 4 3 3 4 3 3 3.28 ± 0.48
T-FAS 5 6 6 6 6 4 4 5.29 ± 0.95
Day 90 T-CSA 789 918 854 847 767 890 756 831.6 ± 62.34
T-CSA-L % 8.78 9.18 7.88 12.06 7.05 7.11 11.76 9.11 ± 2.06
T-ES 3 3 2 3 2 2 3 2.57 ± 0.53
T-FAS 4 5 5 5 5 4 3 4.43 ± 0.78
Day 120 T-CSA 756 977 803 890 802 764 745 805.30 ± 79.06
CSA-L % 7.03 7.46 6.55 6.56 6.87 5.75 7.02 6.75 ± 0.54
T-ES 2 2 3 2 3 3 2 2.42 ± 0.53
T-FAS 4 4 4 4 4 3 3 3.71 ± 0.48
Day 180 T-CSA 815 1096 868 781 769 823 851 857.60 ± 110.80
T-CSA-L % 5.85 14.43 5.89 6.60 6.02 5.55 6.31 7.23 ± 3.19
T-ES 2 7 2 2 3 3 2 3.00 ± 1.80
T-FAS 4 7 4 4 4 3 3 4.14 ± 1.34
Day 240 T-CSA 811 828 769 853 717 808 776 808.00 ± 44.72
T-CSA-L % 5.06 7.98 4.97 7.06 5.74 4.88 5.86 5.93 ± 1.17
T-ES 2 3 2 2 2 2 2 2.14 ± 0.37
T-FAS 3 5 3 3 3 3 4 3.43 ± 0.78
Day 300 T-CSA 698 786 834 803 765 776 853 787.90 ± 50.57
T-CSA-L % 3.07 4.99 3.07 4.83 3.08 3.95 4.04 3.86 ± 0.82
T-ES 2 3 2 2 2 3 2 2.29 ± 0.48
T-FAS 4 4 2 2 2 2 2 2.57 ± 0.97
Day 360 T-CSA 764 769 801 774 890 747 897 806.00 ± 61.91
T-CSA-L % 3.99 4.06 3.05 3.55 3.46 3.04 3.88 3.57 ± 0.42
T-ES 2 2 2 2 2 1 1 1.71 ± 0.48
T-FAS 2 2 2 2 2 1 2 1.85 ± 0.37
T-CSA, total tendon cross-sectional area; CSA-L %, percentage of the cross-sectional lesion; T-ES, total echo-score; T-FAS, total fiber alignment score.
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FIGURE 6 | Effects of plasmid DNA encoding VEGF164 and FGF2 genes in horses with SDFT lesions. The (A) percentage of total cross sectional lesion area,
(B) echogenicity score, (C) fiber alignment score, and (D) cross-sectional area of the suspensory ligament branch at the maximal injury zone. ∗ indicates point at
which p < 0.05 was reached in comparison to day 0.
the recurrent tendon injury in the treated limb. The final
horse (Horse #9, SDFT) sustained an unrelated injury on the
contralateral limb approximately 11 months after treatment
(proximal suspensory ligament desmitis), which precluded
analysis of the outcome, but up until that point sporting activities
had resumed.
Horses were observed for adverse reactions from day 0
until the end of the 12 months study. There were no adverse
reactions in any of the 7 SDFT affected horses as a result
of the application of the pDNA. Prior to treatment, on day
0, the mean degree of lameness was 1.86 ± 0.69 in the
study horses (Figure 1B). In particular horses #6 showed high
degrees of lameness before treatment (Table 2). Compared
to day 0, lameness significantly decreased by day 20 after
treatment to 0.43 ± 0.53 (p < 0.05; Figure 1B). Lameness
was eliminated faster in horses with tendinitis of SDFT than
horses with desmitis of SLB (P > 0.05). At 12 weeks and
persistently in later follow-up examinations, no lameness was
evident by clinical examination in 6 from 7 treated horses,
(horse #5 was affected at days 180 and 240 following recovery
at days 90 and 120). The owners were asked to score their
horses performance 12 months after gene therapy. Athletic
success was reported as good to excellent by six out of
seven owners. The owners of horse #5 (the horse with onset
of lameness following the healing process) could not report
good-excellent athletic success at that point. The age and
gender of horses and duration of lameness did not show
any influence on the clinical outcome after gene therapy. The
FIGURE 7 | Ultrasound images prior to plasmid DNA encoding VEGF164 and
FGF2 genes (A) and 20 (B), 40 (C), 60 (D), 120 (E), 180 (F), 240 (G), and 300
(H) days after administration in horse #6 – SDFT tendinitis. Arrow indicates
lesion.
main differences in the clinical outcomes were observed in
relation to the degree and location of T/L damage before
treatment.
Table 5 and Figure 6 show ultrasonographic findings of the
seven horses with SDFT tendinitis before and after treatment
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with plasmid DNA encoding VEGF164 and FGF2 genes (see
also Figure 7 and Supplementary Figure S2, representative
images from horse #6). The average total percentage of CSA scale
of SDFT involved in the injury, before treatment was 17.44%
(range 12.03–23.38%; Table 5). In two patients (horses #7 and
#10) the core lesion in SDFT presented with a mixed focal,
dishomogeneous, hypo-echoic area. The other horses with acute
SDFT tendinitis before treatment presented with marginal (three
limbs) and diffuse lesions (two limbs), with loss of the normal
fibrillary pattern (Table 5). The damage of SDFT was primarily
seen on the forelimbs (Table 5). The maximum injury zone of
most lesions of the SDFT was located in zones 1 and 2 (Table 5).
Horse #8 prior to treatment presented with acute SDFT lesions
in zone 3c, in addition to mild damage and a thickening of
the annular ligament and accumulation of the synovial fluid
within the fetlock tendon sheath. In all cases of tendinitis of
SDFT, the contralateral limb had no significant abnormalities.
Horse #9 prior to treatment showed ultrasonographic signs
of scarring of the SDFT in the contralateral non-lame limb
(day 0). The CSA of the affected SDFT limb at the time
of treatment was larger than the CSA of the contralateral
normal limb, consistent with injury. The mean T-CSA of the
SDFT before treatment was 972.9 mm2 (range 867–1272 mm2)
(Table 5).
The ultrasound characteristics of SDFT lesions in most horses
started to improve at 20 days after treatment. This positive
rearrangement trend by SDFT healing process was constantly
maintained in later follow-up days. When the horses started
their exercise program, tendon architecture showed even better
recovery, demonstrated by their longitudinal alignment and
length. On 20 day after treatment, it was observed that T-CSA-
L in %, T-ES, T-FAS, and T-CSA (Figures 6A–D, respectively),
were better in all SDFT- patients, with an appreciable tissue
filling of lesions, but the degree and rate of change of
these ultrasonographic parameters in the further course of
time went different ways (Table 5). For example, during the
observational period of 12 months, it was noticed that there
was a reduction in size of the T-CSA (in mm2), but the
changes were not significant (Figure 6D). Compared to the
contralateral SDFT limb, T-CSA was not significantly higher
during the whole observation period. The T- CSA-L % (Table 5
and Figure 6A) of the SDFT-lesions horses decreased at day
40 after treatment in all horses, except for one horse (horse
#9), which showed a higher % CSA-L. Total mean CSA-L
in % showed a continuous decrease over time, which was
significant (p < 0.05) for the first time on day 60, when
compared to day 0 (Figure 6A). Constant reduction of the total
percentage of the cross-sectional SDFT lesion was recorded in
later follow-ups at 90, 120, 240, 300, and 360 days. Only on
day 180, a mild increase of the percentage of T-CSA-Lesion was
observed, however, horse #5 had a recurrence of damage at that
point.
The echogenicity score of the SDFT lesion (T-ES) after
treatment, decreased continuously and significantly from days
0 to 60 in all horses, except for horse 8, which showed an
increase in T-ES between days 40 and 60. The echogenicity
score had significantly decreased (p < 0.05) by day 20
FIGURE 8 | Transverse and longitudinal color Doppler ultrasonography
projections prior to plasmid DNA encoding VEGF164 and FGF2 genes (A) and
20 (B), 40 (C), 90 (D), 180 (E), 360 (F) days after administration in horse
#3 – SLB desmopathy.
(Figure 6B). Finally, at 3 months after the treatment, the
echo-texture in the most horses was more regular and the
collagen fibers were most oriented in parallel to the longitudinal
axis.
The scores for linear fiber pattern (T-FAS) improved during
the course of the study in horses with SDFT lesion, but
slowly in comparison with the echogenicity score (Figure 6C).
T-FAS was significantly (p < 0.05) decreased for the first
time on day 60. Constant decreases in the total scores for
linear fiber patters and echogenicity scores were noticed in
later follow-ups study days, but on day 180 a mild increase in
these ultrasonographic parameters was observed. This happened
concomitantly with the reoccurrence of damage observed in
horse #5. After 9 months, signs of tendon lesions could only
be detected with difficulty in most SDFT injured horses, as
they showed notably correct alignment and a well-organized
longitudinal pattern.
The evaluated T/L lesions using CDU showed that in
most horses with SDFT tendinopathy before treatment, only
small color foci that were rhythmically blinking at the
lesion area were present. The average color Doppler scores
for vascularization of maximal inquires zone for SDFT and
SLB before treatment was 1.13 (±0.30), slightly elevated
in comparison to healthy contralateral limbs (0.8 ± 0.52).
Color Doppler scores for vascularization of maximal inquires
zone for SDFT and SLB after treatment with the plasmid
DNA encoding VEGF164 and FGF2 genes, revealed a notable
increase in scores by just day 20 (2.37 ± 0.60; Table 4
and Figures 4B, 8). This trend lasted up to 90–120 days,
with a maximum score achieved on day 40 (2.83 ± 0.35).
The CDU scores in most animals then gradually decreased
to basal indices (as in healthy limbs) after 180 days of
treatment, indicating blood flow patterns similar to day 0
(Figure 4). No significant correlation was observed between
the severity of T/L lesions prior treatment and CDU scores
after treatment. There were no significant differences in the
CDU scores between the SDFT and the SLB horses, after
Frontiers in Pharmacology | www.frontiersin.org 12 August 2018 | Volume 9 | Article 978
fphar-09-00978 August 28, 2018 Time: 20:12 # 13
Kovac et al. VEGF164/FGF2 Equine Lameness Gene Therapy
treatment, therefore the changes in CDU-scores were strictly
individual.
DISCUSSION
Tendon or ligament healing is a long process and is dependent
upon the severity and size of the lesion. Various therapies for
T/L lesions have been described previously; however, injury
recurrence rate is high even after long recovery periods and
none of these therapies results in complete tissue regeneration.
Previously we demonstrated for the first time that direct gene
therapy using injected plasmid DNA encoding species-specific
VEGF164 and FGF2 cDNAs resulted in rapid recovery (2–
3 weeks) of suspensory ligament branch and SDFT injuries in
two horses (Kovac et al., 2017). In the current continuation
and extension of the previous study we treated 10 cases in
order to restore naturally occurring moderate and severe injuries
of the SDFT and branches of the suspensory ligament, with
a more rapid exercise program than is traditionally applied
in equine T/L lesions (Godwin et al., 2012). According to
our clinical observations, the direct gene therapy in 9 out of
10 horses resulted in an earlier reduction of the degree of
lameness. The rehabilitation time was also significantly reduced
to just 20 weeks which represents just 50% of a usual recovery
period for equine tendon/ligament injuries (Reef, 2001). By
2–6 months after the completion of the treatment 9 of the
horses showed a successful return to their pre-injury level
of sports load, in our cases this was the use of horses in
dressage or pleasure/riding. It is important to emphasize that
traditionally absolute tissue regeneration is not to be expected
even when lameness has subsided following treatment of equine
tendinitis. In our study, we observed a rapid regeneration of
both the SDFT and the suspensory ligament in most horses
within 2–6 months of treatment by measuring the total cross
sectional area, percentage of cross sectional area of the lesion,
the echogenicity score, and the percentage of parallel collagen
fibers. Ultrasonographic characteristics of T/L lesions started
to improve notably at 3 weeks. This trend was constantly
maintained in later follow-ups. Intensive training of a horse
can be integrated into the regime once ultrasound examinations
confirm almost complete healing of the injured T/L. When
the horses in our trial started the exercise program tendon
architecture further improved, which was demonstrated by their
longitudinal alignment and length. Partly, these effects could
be explained with a coincidence with conditions and phases of
normal T/L healing. Nevertheless, our data reflect cases of middle
to severe T/L lesions and such values are usually associated with
a poor prognosis.
No systemic adverse reactions were observed as a result of
the application of the plasmid DNA encoding species-specific
VEGF164 and FGF2 cDNAs. The horse that was not responsive
to treatment, remained lame during first 3 months after treatment
had presented with severe damage to the branch and body of SL.
Only one sound horse after rehabilitation (originally presenting
with tendinitis of the SDFT) experienced re-injury 6 months
after treatment. Twelve months after treatment, 8 out of 10 horse
owners judged the outcome of their horses after gene therapy
in terms of athletic success as good to excellent. According to
our observations, the age and gender of horses and duration
of lameness prior to treatment did not show any influence
on the clinical outcome after gene therapy. The main factor
affecting clinical outcome came from the degree and location
of T/L damage before treatment. The data obtained in this
clinical study are encouraging and reveal that there could be
remarkable positive changes in the early stages of injury healing
of both equine tendinitis and desmitis, if defect areas are directly
treated with plasmid DNA encoding species-specific VEGF164
and FGF2 cDNAs. Partly, these effects could be explained with
a coincidence with conditions and phases of normal tendon
healing. Nevertheless, our data reflect only cases of moderate or
severe tendon lesions; such values are well known to be associated
with a poor prognosis in response to the standard methods of
treatment.
A limitation of the present clinical study was the fact that
the investigation did not determine the exact mechanism of
action of the of direct gene therapy with pBUDK-ecVEGF164-
ecFGF2 on healing the injured equine tendons and ligaments.
Because of a lack of previous reports on results of treatment
in this manner of equine tendinitis and desmitis, we cannot
compare our results with results of other treatments. Based
on some previous studies, growth factors VEGF and FGF2 are
proteins which are primarily released by platelets, fibroblasts and
endothelial cells at the site of injury (Byrne et al., 2005). Their
mechanisms of action are complex and closely related to other
factors of inflammation and regeneration. They are considered to
stimulate migration of tendoblasts, fibroblasts and mesenchymal
stem cells which are responsible for production of collagen
and other constituents of extracellular components of ligaments
and tendons such as proteoglycans, glycosaminoglycans and
glycoproteins, via enhanced angiogenesis (the process of new
blood vessel formation) at a site of injury (Martinek et al.,
2005).
An increased number and intensity of the vessels signals
in T/L lesion area after treatment detected by the CDU was
observed in our study. Evaluated lesions using CDU showed
in most horses before treatment, only small color foci that
were rhythmically blinking at the lesion area. Color Doppler
scores for vascularization of maximal inquires zone revealed a
notably increase in scores by just day 20 following treatment.
This increase lasted up to 90–120 days, with maximum on
day 40. The changes in CDU-scores after treatment were
strictly individual. The CDU scores in most our study horses
then gradually decreases to basal indices after 180 days of
treatment. These changes in CDU scores could be explained,
by the fact that normal T/L is hypovascular, and angiogenesis
or increased vascularity are associated with an acute injured
observed in the proliferative but not in the remodeling
phase of the tendon healing (Carvalho et al., 2013), i.e.,
hypervascularity is normal in the healing process. According
our observations there was no significant correlation between
severity of T/L lesions prior treatment and CDU scores after
treatment. In other words, the positive signals of blood flow
might be due to transient increases of blood flows in the
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inherent vessels in response to hypoxia of tendon tissue
associated with injury. According to Hatazoe et al. (2015), a
semi-quantitative determination of blood flow in the equine
tendon might offer a new method for differentiating between
active and inactive inflammation in the tendon associated
with the injuries, as well as in deciding the time course
of injured tendon bundles. We propose that this effect of
angiogenesis is notably enhanced after VEGF164 and FGF2 gene
therapy.
We hypothesized that the transfer of FGF2 and VEGF164
genes into equine T/L would augment production of growth
factors and collagens that would significantly enhance the healing
strength over a critical period of the tendon healing. The FGF2
gene was chosen for a number of reasons. Firstly, FGF is
one of main growth factors for tissue repair, and its major
action is in the promotion of collagen production, tendon
development, proliferation of tenocytes and it also plays a
role in promoting the expression of a series of other growth
factor genes (Tang et al., 2016). Additionally, FGF is down-
regulated during tendon repair under normal circumstances
and low levels of FGF may be a principle reason for poor
healing potential of the tendon (Tang et al., 2014). The vascular
endothelial cell growth factor (VEGF) gene was chosen for
a number of reasons. This growth factor is one of the most
important angiogenic factors in tendon healing, but under
normal circumstances, there are low levels of VEGF expression
in the tendon (Berglund et al., 2011). VEGF also enhances
collagen production through MAP kinase signaling pathways
and increases vascular permeability through the synthesis of
endothelial platelet-activating factor (Brkovic and Sirois, 2007).
In combination FGF and VEGF increase proliferation and
prohibit apoptosis of tendon fibroblasts and effectively correct
the insufficiency of the tendon healing capacity (Tang et al.,
2016). It has also been suggested that the FGF upregulation may
represent an early, sustained signal for angiogenesis (Stavri et al.,
1995).
Gene therapy, as one of the most advanced technologies
in medicine, is a promising therapy for hereditary diseases
and additionally offers novel opportunities for the clinical
treatment of numerous orthopedic disorders including injuries
of the tendon and ligament (Evans et al., 2009; Bosch et al.,
2011; Tang et al., 2016). The use of direct gene therapy with
these specific growth factors is also highly promising for the
treatment of orthopedic disorders not only in horses but in
other animal species and humans (Rizvanov et al., 2018). The
successful application of direct gene therapy with a similar
plasmid construct based on dog-specific VEGF164 and bone
morphogenetic protein (BMP2) genes for the treatment of
an injury of the anterior cruciate ligament in a large breed
dog has been reported previously (Zakirova et al., 2014).
Moreover, in a human clinical case report gene therapy pDNA
encoding VEGF and FGF2 genes were used for the treatment
of patients with critical lower limb ischemia (Plotnikov et al.,
2012). Finally, plasmid DNA pl-VEGF165 (officially registered as
Neovasculgen), encoding human VEGF165, demonstrated safety
and efficacy in patients with chronic lower limb ischemia for the
treatment of atherosclerotic peripheral arterial disease without
side effects (Deev et al., 2015, 2017). The high efficacy and safety
of the direct pDNA gene therapy has been demonstrated in all
of these cases. It should be noted that there are other methods
also widely used in the literature. A number of vectors (including
plasmid, lentivirus, adenovirus, adeno-associated virus and other
modified virus platforms) and delivery systems (including
lipofection, cationic nanoparticles, polymers, dendrimers) have
been utilized (Dunbar et al., 2018; Rizvanov et al., 2018). Our
approach using naked plasmid DNA was considered appropriate
as the safest way to administer gene therapy as other approaches
can suffer from higher toxicity, immunogenicity and even
oncogenic potential (in case of integrating viral vectors). In
order to achieve a high efficiency with naked pDNA, several
injection points were performed (at a distance of 0.5–1 cm from
each other) into both damaged and adjoining normal tissue,
to ensure a more complete tissue infiltration. Future trials will
include the use of delivery systems in order to ensure optimal
efficacy.
Vascular endothelial cell growth factor levels peak following
inflammatory reactions and this is especially notable during
the proliferative and remodeling phases. FGF2 and VEGF gene
therapy in vitro and in vivo with adeno-associated viral vectors
in avian flexor tendons showed increased type I collagen plus
other extracellular molecules, accelerated cellular proliferation
and improvement in tendon strength and elasticity (Tang et al.,
2016).
The clinical and ultrasound data obtained in this study
are encouraging but based on a relatively small number of
horses, referred for various degrees and locations of T/L
lesions. Despite the number of clinical cases, this method
of using direct gene therapy for the treatment of T/L
injuries in horses is unique and highly promising, however, it
requires further research. In order to further assess the direct
effects of VEGF and FGF2 gene therapy on the healing of
injured tendons and ligaments in horses, evaluation of large
numbers of experimental animals with extended follow-up
times and randomized controlled clinical trials or a double-
blind study is required. A more comprehensive and detailed
mechanistic approach would also be obtained by obtaining
histological samples and undertaking immunohistochemistry
on biopsy materials. Factors such as gene expression levels
within the tissues, analysis, identification and quantification
of the collagens, functional and intracellular distributions
of the proteins and further studies into the biochemistry
of the pathological process would all help to ascertain the
underlying mechanisms of action. Introducing gene therapy into
veterinary medicine clinics is becoming an increasing reality,
however, there are a number of challenges which must be
solved. This study makes significant advances in the use of
gene therapies and in the mechanisms underlying the healing
process.
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